A healthcare and life sciences focused venture capital firm based in US and China has managed $600 million USD in total assets, including both USD and RMB funds. The firm has invested in over 50 companies with 10 successful IPO and acquisitions. The firm seeks Series A to Series B opportunities in healthcare and life sciences. Typical check size ranges from $5-15 million USD. The firm prefers to lead, especially for US and China based deals but is open to co-investing. The firm primarily considers companies based in the US and China but is open to opportunities globally.
The firm looks for new opportunities in therapeutics, medical devices, medical services, the diagnostics (IVD) space and healthcare IT. The firm is opportunistic in terms of subsectors and indications. For therapeutics, the firm would like to see some clinical data or safety data.
The firm does not have specific requirements for the management team. Management teams with successful track records would be preferable. The firm will likely seek board seats on a case-by-case basis.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Hot Investor Mandate: Western Europe-Based Firm Invests Globally in Life Sciences & Healthcare Companies With Inaugural Fund
A Venture Capital firm based in Western Europe invests exclusively in the life science space and is currently investing out of their first fund. The firm looks to invest in early-stage life science companies crossing all sectors and is opportunistic in terms of subsector and indication. The firm focuses on Pre-Seed, Seed, Series A and Series B investments and investments are in the form of equity. The firm makes investments ranging from $50K to $3M per round. The firm will consider opportunities globally.
In the life sciences, the firm is looking for new investment opportunities in the therapeutics, diagnostics, digital health, medical device and femtech sectors. The firm is open to pre-clinical therapeutic companies and all three classes of medical devices. The firm has a broad investment interest and is opportunistic in terms of sub-sectors and indications.
The firm looks for all types of management teams, however a proven track record is a plus. The firm is open to both leading and co-investing. If the firm leads, they seek board seat representation.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Hot Investor Mandate: VC Firm with US & China Operations Invests in Early and Growth-Stage Novel Therapeutics Companies Globally
The firm is a life science venture capital firm with strong China expertise and global capabilities. Founded in 2017, the firm discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. They operate offices in Boston, Shanghai, as well as Palo Alto.
The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage.
The firm has no specific requirement for the company & management team.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Hot Investor Mandate 4: New USA-Based Fund Invests in Seed Stage Digital Health Companies Targeting Oncology
A venture capital firm founded in 2022 and headquartered in the US invests in cancer-focused data accessibility and scalability, infrastructure, education and access, and IT and service start-ups as they look to fundamentally change the way cancer care is designed and delivered at scale. Drugs, therapeutics, or medical devices are not of interest. The firm will invest in Seed stage companies that are currently selling in the market. The firm is open to global companies, typically allocating between $250k-1.5M USD. The firm can act as a lead investor and co-investor.
In terms of life science, the firm invests in cancer-focused digital health companies, however, does not invest in drugs, therapeutics, medical devices, and technologies that require FDA approval.
The firm does not have specific management team requirements and does not require to take a board seat.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Congratulations to the RESI JPM Innovator’s Pitch Challenge Winners!
By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
At RESI JPM, we had 56 companies participate in the Innovator’s Pitch Challenge (IPC). These finalist companies pitched to an audience and fielded questions from an investor judges panel, as well as exhibited a poster showcasing their technology at the conference.
Registered RESI attendees (startup executives, early-stage investors, and industry experts), ‘invest’ or vote for their favorite IPC company with RESI cash provided, based on the pitch company’s poster board displayed at RESI’s exhibit hall and their performance in the Q&A portion of their pitch session.
Life Science Nation is pleased to share the winners who received the most votes during the RESI JPM. Congratulations to the winners!
1st Place – Cardathea
Cardathea has the potential to disrupt the $16B cardiac pacing systems market by making fast, easy, reliable “conduction system pacing” (CSP, considered the gold standard by rhythm societies around the world but currently only done ~1% of the time due to lack of needed tools) finally possible with its EFI (electric field imaging) system. A pacing system manufacturer with exclusive access to our system would have an unfair advantage as pacing practice shifts from current methods to CSP. A 5% shift in market share is worth >$1B to a pacing system acquirer … not counting revenue from our system. Cardathea has already used its non-invasive imaging and guidance system in 8 pigs and 14 people.
Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | Rick Berenson, Founder & Serial Entrepreneur, Cardathea | Brian Craig, Founder & Medical Device Commercialization Wiz, Cardathea
2nd Place – Convergence Medical
Convergence Medical Pty Ltd is a Brisbane based medical device company, focused on the advancing arthroscopy with design and development of the world’s first arthroscopic robot (the V01 – Arthroscopic Surgical Robot).
We exist to address the significant problems in arthroscopic surgery, improving the lives of the 50 million patients treated every year and the 30 thousand surgeons who perform these operations.
The V01 is developed to change practice by providing ridged stability and robotic precision, power by an immersive and intuitive interface making operations simpler and more efficient. These innovations are designed to help the 70% of surgeons who perform these procedures and regularly experience significant muscular skeletal pain, the 30% of surgeons forced to retire early, the third of surgeons that state they don’t feel confident with their abilities and the 40% of patients which have observable damage during an operation.
Cameron Hurlburt, Director of Business Development – West Coast (US), LSN | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | Chris Jeffery, CEO, Convergence Medical
3rd Place – Gelomics
Gelomics fast-tracks drug development by enabling pharmaceutical companies to grow human tissues as an ethical, economical, and highly predictive alternative to animal experiments. The company has validated its MVP with 200+ paying customers in 22 markets, achieving >30% MoM revenue growth, >80% demo-to-sales conversion, and >$500,000 in sales, all through self-funding efforts. In Q4 2023, Gelomics closed its $2m pre-seed round and secured an additional $1.15m in non-dilutive funding to progress its R&D pipeline and enter the Drug Development Technology market, addressing a TAM of >$100bn. The company is seeking to expand its network of US-based venture capital and strategic partners in preparation for its next major investment round and the strategic entry into the US market.
Momo Yamamoto, Investor Research Analyst, LSN | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | Christoph Meinert, PhD, CEO & Co-Founder, Gelomics
You are Invited to Join LSN in Atlanta, Georgia, for RESI South, and Barcelona, Spain, for RESI Europe
By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
Life Science Nation (LSN) is excited to announce two significant RESI partnering events in 2024. The first, RESI South, will be held in Atlanta, Georgia, on March 25, and the second, RESI Europe, will occur in Barcelona, Spain, on June 17th. These events mark a strategic expansion of LSN’s global partnering platform, providing a unique opportunity for its network of capital investors and licensing partners to engage with two dynamic innovation regions. The Super Early Bird rates are currently available for two upcoming RESIs. This is an excellent opportunity to register at a reduced cost before the deadline.
RESI South in Atlanta is particularly significant as it will showcase the burgeoning life science innovation ecosystem in the Southeastern United States. The Southeast LifeSci Investor Coalition, representing seven southern states (AL, FL, GA, NC, SC, TN, and VA), has united to spotlight the region’s wealth of early-stage drugs, devices, diagnostics, and digital health technologies. Thousands of startups are invigorating this innovation region. LSN estimates that hundreds of startups with technology transfer licenses are ready to explore the partnering opportunities that RESI South will bring.
The untapped potential of the Southeast is underscored by its receipt of 5.5 billion in NIH funding and 8.3 billion in academic research expenditures, making up 16% of all academic Bioscience R&D U.S. funding. LSN is thrilled to partner with the Southeast LifeSci Investor Coalition and is confident that its global partnering network will be able to explore this previously underserved market.
Following RESI South, LSN will host RESI Europe in Barcelona, Spain. The BioRegion of Catalonia has emerged as a leading force in the global life science landscape, boasting a thriving biotech and medtech startup ecosystem. The region’s strategic focus on business automation, connectivity, and the application of AI within diagnostics and treatments has attracted international life science players and positioned Catalonia as a hub for advanced therapeutics.
RESI Europe in Barcelona will leverage the BioRegion and showcase the broader Spanish life science ecosystems. RESI Europe also provides a great opportunity for global startups in Europe, North America, and APAC to get to Europe and meet the early-stage global players in the LSN European network. LSN expects a strong showing from its global capital investor and licensing partner network to attend this inaugural event.
LSN’s RESI Partnering Events in 2024 are set to provide a unique platform for global investors and startups to engage with two vibrant innovation regions. These events underscore LSN’s commitment to fostering cross-border partnerships and driving innovation across the global life science landscape. For more information about LSN and its initiatives, you can visit their official website at Life Science Nation.
RESI JPM Recap: Record Investor Registrations and 3000 Connections Made
By Karen Deyo, VP of Product, Israel BD, LSN
Life Science Nation’s (LSN) biggest Redefining Early Stage Investments (RESI) event of the year, taking place during JP Morgan Healthcare week in San Francisco, was a huge success last week. With over 3000 meetings and connections made through RESI, it will be weeks before the true outcomes will be fully realized. With over 1100 attendees, spanning 35 countries and 5 continents, RESI hit a record high investor registrations, with 650 investors registered to attend, both in person and virtually. Of these investors, one third were investors who were new to RESI. RESI is the premier event for investors wanting to connect with early stage life science startups, and for every event, the LSN Investor Research team received outreach from new investors interested in joining our network and connecting with exciting new innovators.
In addition to meetings, RESI’s compelling content provides startups with opportunities to learn from investors, industry experts and their peers tips and techniques to make their fundraise successful. With panels such as the Family Offices, Big Pharma, Health System Partners and Cross Border Investors, companies were able to learn how different investor types partner in the early stages, and how to approach these investors most successfully. Other panels covered different sectors, such as Early Stage Therapeutics and Medical Devices, and even focused on areas gaining increasing traction such as Mental and Behavioral Health. These investor panels focused on current trends in the industry, and where they think it is headed in the near future. Panels hosted by industry experts focused on challenges companies can face and experts that can help them avoid issues that can delay them in their quest to bring their technologies to market. Cambridge Scientific hosted a session on procuring space in incubators and labs, as well as equipment, and how to navigate that to best advantage. Husch Blackwell hosted a session on navigating a fundraise with a complex technology, and how to explain your technology to best advantage when there is a complicated regulatory and intellectual property landscape.
The LSN network continues to expand with every RESI we organize, with new attendees and new content, and we are excited for 2024, which will include several new locations hosting our RESI conference. Check out our schedule for 2024, and join us for what is sure to be a full year of fantastic events.
Next Phase Newsletter 